Collplant Biotechnologies Ltd represents values of innovation, sustainability, and excellence. Their corporate philosophy revolves around developing and commercializing advanced technologies in the field of regenerative medicine. Through their unique plant-based recombinant collagen technology, Collplant aims to provide groundbreaking solutions for tissue repair and organ transplantation. With a commitment to scientific research and development, they strive for constant improvement and expansion of their product portfolio. Collplant Biotechnologies Ltd is dedicated to improving the quality of life for patients and addressing critical medical needs globally through their pioneering biotech solutions.

Collplant Biotechnologies Ltd is primarily present in Israel.

Collplant Biotechnologies Ltd has achieved several significant milestones. One notable milestone is the successful development and commercialization of its proprietary plant-based recombinant human collagen bio-ink, known as RhCollaGel. This breakthrough technology has various applications in the field of regenerative medicine, including tissue engineering and 3D bioprinting. Collplant has also established strategic partnerships with leading companies and organizations globally to advance its innovative products. Additionally, the company has received regulatory approvals for its products, further strengthening its position in the market. These achievements highlight Collplant Biotechnologies Ltd's commitment to revolutionizing the field of biotechnology with its cutting-edge technologies and collaborations.

The history and background of Collplant Biotechnologies Ltd can be traced back to its establishment in 2004. Collplant is a leading regenerative medicine company that specializes in the development and commercialization of innovative plant-based bio-inks and biomaterials for medical applications. With a strong focus on plant-derived recombinant human collagen technology, the company aims to address unmet medical needs in the fields of tissue repair, wound healing, and aesthetics. Collplant's cutting-edge technology has garnered global recognition, allowing it to establish strategic partnerships with renowned companies across various industries. Over the years, Collplant Biotechnologies Ltd has become a key player in the field of regenerative medicine, driving advancements in therapeutic solutions and bringing significant value to patients worldwide.

The main competitors of Collplant Biotechnologies Ltd in the market are companies such as Organovo Holdings, Integra LifeSciences, and Vermillion.

Collplant Biotechnologies Ltd primarily operates in the biotechnology and medical industries.

The business model of Collplant Biotechnologies Ltd focuses on developing and commercializing medical products based on its proprietary plant-based recombinant human collagen (rhCollagen) technology. Collplant utilizes plant species to produce rhCollagen, which has similar characteristics to human collagen. This advanced technology allows the company to address various medical needs, such as tissue repair, dermatology, orthopedics, and more. Collplant aims to become a key player in the regenerative medicine market by leveraging its innovative platform and collaboration with strategic partners.

Collplant Biotechnologies KGV ir -3,89.

Collplant Biotechnologies KUV ir 33,07.

AlleAktien kvalitātes vērtējums Collplant Biotechnologies ir 2/10.

gaidāmā Collplant Biotechnologies apgrozījums ir 1,72 milj. USD.

gaidāmā Collplant Biotechnologies peļņa ir -14,66 milj. USD.

CollPlant Biotechnologies Ltd is an Israeli company specializing in the development and production of biotechnological products from plant cell cultures. The company's business model consists of two main divisions: medical and cosmetics. In the medical field, CollPlant Biotechnologies Ltd produces collagen-based products used in soft tissue reconstruction, wound healing, and tissue engineering. The company uses proprietary technology to extract human collagen from tobacco plants, which has higher purity and biocompatibility than other collagen-based products on the market. CollPlant Biotechnologies Ltd offers various medical products, including bio-implants for tendon injuries, eyelid implants for weak eyelid muscles, and nasal implants for nasal tip reconstruction. The company is also working on the development of 3D-printed artificial tissues such as skin, bone, and cartilage to be used in regenerative medicine. In the cosmetics industry, CollPlant Biotechnologies Ltd produces plant collagen-based ingredients for skincare. These products moisturize the skin and improve its elasticity and firmness. The company also manufactures collagen-rich face masks designed to promote the skin's own collagen production. CollPlant Biotechnologies Ltd has a strong presence in the Asian market, where the demand for plant-based cosmetic products is rising. The company has distribution agreements with various international companies to sell its products worldwide. It also partners with research and development companies and academic institutions to further develop its technologies and products. These partnerships allow CollPlant Biotechnologies Ltd to reduce research costs and benefit from the expertise of other companies and institutions. The company's business model relies on innovative technologies and biotechnological products that give it a competitive advantage in the market. It focuses on diversifying its product range across various industries to minimize risk and maximize profits. Through its distribution and partnership agreements, CollPlant Biotechnologies Ltd is able to sell its products worldwide and expand its market presence. Overall, CollPlant Biotechnologies Ltd has become a key player in the biotechnology industry with a promising future. With its innovative technology and diversified products, the company is well-positioned to meet the needs of customers in various industries and continue its growth.

Collplant Biotechnologies izmaksā dividendes 0 USD, kas tiek izmaksātas reizes gadā.

Dividendes pašlaik nevar aprēķināt Collplant Biotechnologies vai uzņēmums nedod dividendes.

Collplant Biotechnologies ISIN ir US19516R1077.

Collplant Biotechnologies WKN ir A2PMPX.

Collplant Biotechnologies simbols ir CLGN.

Pēdējo 12 mēnešu laikā Collplant Biotechnologies maksāja dividendes apmērā. Tas atbilst aptuveni dividendes ražībai. Nākamajos 12 mēnešos Collplant Biotechnologies plāno maksāt dividendes 0 USD apmērā.

Collplant Biotechnologies pašreizējā dividendu rentabilitāte ir .

Collplant Biotechnologies maksā dividendes ceturksnī. Tās tiek izmaksātas mēnešos .

Collplant Biotechnologies pēdējo 0 gadu laikā katru gadu izmaksāja dividendes.

Nākamajiem 12 mēnešiem tiek prognozētas dividendes apmērā 0 USD. Tas atbilst dividendes ražībai 0 %.

Collplant Biotechnologies tiek piešķirts nozarei "Veselība".

Lai saņemtu pēdējo dividendu Collplant Biotechnologies apmērā 0 USD, kas tika izmaksāta 27.09.2024., tev akcija bija jāpatur depozītā līdz Ekss dienai, kas bija 27.09.2024..

Pēdējās dividendes izmaksa notika 27.09.2024..

Gadā 2023, Collplant Biotechnologies izmaksāja 0 USD dividendes.

Collplant Biotechnologies dividendes tiek izmaksātas USD.